ruxolitinib + methylprednisolone
Phase 2- Indications
- Relapsed/refractory multiple myeloma
Company intelligence / Profile preview
ONCOtherapeutics
West Hollywood, California, United Statesoncotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
ONCOtherapeutics does not develop its own drugs but manages and oversees clinical trials for hematology and oncology therapies. It has supported studies evaluating agents such as ruxolitinib in multiple myeloma but does not sponsor these programs itself.
- Therapeutic areas
- HematologyOncology
- Modalities
- N/A
- Industry
- Contract Research Organization
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly listed; works with biopharma clients on contract basis.
Beyond the preview
Go deeper on ONCOtherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONCOtherapeutics.